Responsible by design is how SCILEX leads by example. We’re committed to harnessing the power of revolutionary delivery technologies designed to safely and effectively provide therapies to those who need them most. With a passion for patients and a dedication to innovation, SCILEX is lighting the way forward in pain management.
Sorrento Subsidiary, SCILEX Pharmaceuticals Announces Key Endpoints Met in Pivotal Bioequivalence Clinical Study for Its Lead Product, ZTlido™
– 505(b)(2) NDA resubmission is expected in mid-2017 SAN DIEGO, Dec. 5, 2016 /PRNewswire/ — SCILEX Pharmaceuticals Inc. (“SCILEX”), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) today announced that its pivotal study for lead investigational product, ZTlido™ (lidocaine patch 1.8%), has met a primary endpoint establishing comparative pharmacokinetics and a secondary endpoint of bioequivalence … Continue reading Sorrento Subsidiary, SCILEX Pharmaceuticals Announces Key Endpoints Met in Pivotal Bioequivalence Clinical Study for Its Lead Product, ZTlido™
Re-engineering pain management
At SCILEX, we believe that innovation is the path to improving therapeutic outcomes in pain management. We believe our advances in this area are evidence of our tireless dedication to optimizing the patient experience.